New Vaccine Development Establishing Priorities: Volume II, Diseases of Importance in Developing Countries (1986) / Chapter Skim
Currently Skimming:
Appendix J: Preface to Volume I
Appendix J: Preface to Volume I
Pages 421-422
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 421... ...
The Committee on Issues and Priorities for New Vaccine Development was established in the Institute of Medicine's Division of Health Promotion and Disease Prevention. Careful selection of members produced a committee with the collective expertise necessary to conduct a study of this scope; research virologists, bacteriologists, physicians, economists, epidemiologists, sociologists, public health experts, and industry leaders all have made signif icant contr ibutions to the final product.
|
From page 422... ...
Among the factors that NIAID requested be considered in developing the priority setting approach were: . scientific and technical readiness · opportunities for safety and efficacy testing · socioeconomic impact, including the incidence, prevalence, severity, and cost of the target condition; and where feasible, the cost-effectiveness of potential vaccines · social impact, including legal and ethical problems, patient and provider acceptance, special problems with certain populations (e.g., immunization of pregnant females or young infants)
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.